Olaplex Holdings, Inc.

OLPX: 15-12G · acquisition merger

Olaplex Holdings, Inc. has filed a Form 15 to terminate the registration of its Common Stock under Section 12(g) of the Securities Exchange Act of 1934 and suspend its duty to file reports under Sections 13 and 15(d). This action follows the completion of the company's merger with Henkel US Operations Corporation on July 7, 2026, where Olaplex became a wholly-owned subsidiary of the Parent entity. Consequently, the company has certified that it has approximately one holder of record as of the date of this notice.

SEC 15-12G•3mo ago

OLPX: 8-K · acquisition merger

Olaplex Holdings, Inc. (OLPX) has completed its merger with Henkel US Operations Corporation, becoming a wholly owned subsidiary of Henkel. The transaction was valued at approximately $1.4 billion in total equity value. Shareholders received $2.06 per share in cash as merger consideration. In connection with the deal, Olaplex repaid approximately $357.6 million in outstanding debt under its credit agreement with no early termination penalties. Olaplex has requested delisting from the Nasdaq Global Select Market and intends to terminate its registration under the Securities Exchange Act of 1934. The company’s board of directors was replaced, with new directors appointed by Henkel, and the 2026 Annual Meeting of Stockholders was canceled.

SEC 8-K•3mo ago

OLPX: DEF 14A · proxy statement

Olaplex Holdings, Inc. filed its definitive proxy statement for the 2026 annual meeting of stockholders, scheduled for July 9, 2026. The filing outlines three proposals: the election of four Class II directors, an advisory vote on executive compensation for fiscal year 2025, and the ratification of Deloitte as the independent auditor. The proxy statement reveals that Olaplex reported a net loss of $9.3 million for fiscal year 2025, though adjusted EBITDA reached $93.9 million. This non-GAAP measure excludes significant items including $53.9 million in depreciation and amortization, $26.5 million in net interest expense, and $13.3 million in share-based compensation. The filing confirms the pending merger with Henkel US Operations Corporation, noting that the Tax Receivable Agreement will terminate upon the merger's effective time. Advent Funds remain the controlling shareholder with a 74.3% stake, while Mousse Partners holds 5.7%. The document also discloses a $10.5 million acquisition of Purvala Bioscience in August 2025 and $9.1 million in litigation costs related to the Lilien securities class action.

SEC DEF 14A•4mo ago

Notice of Settlement of Shareholder Derivative Actions

Olaplex Holdings announced a proposed settlement of shareholder derivative litigation, subject to court approval at a hearing on July 27, 2026. The settlement requires Olaplex to adopt corporate governance reforms and pay $700,000 in attorneys' fees to plaintiffs' counsel, with $2,500 service awards for each of the three plaintiffs. Defendants deny all allegations of wrongdoing, and the notice explicitly states this is not a class action with no monetary recovery for shareholders beyond the dismissal of claims.

•4mo ago